- Home
- KLXE vs BOLD Comparison
KLXE vs BOLD Comparison
Compare KLXE & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | KLXE | BOLD |
|---|---|---|
| Founded | 2018 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 26.2M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | KLXE | BOLD |
|---|---|---|
| Price | $1.79 | $1.10 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 142.0K | ★ 167.7K |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $645,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $1.00 |
| 52 Week High | $7.40 | $3.54 |
Technical Indicators
Market Signals| Indicator | KLXE | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.09 | 39.65 |
| Support Level | $1.54 | $1.00 |
| Resistance Level | $1.70 | $1.18 |
| Average True Range (ATR) | 0.11 | 0.08 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 95.24 | 42.31 |
Price Performance
Historical ComparisonAbout KLXE KLX Energy Services Holdings Inc.
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.